Enfusion Inc’s recent filing unveils that its Chief Accounting Officer Gutowski Valeria unloaded Company’s shares for reported $6167.0 on Feb 28 ’25. In the deal valued at $11.42 per share,540 shares were sold. As a result of this transaction, Gutowski Valeria now holds 49,616 shares worth roughly $0.57 million.
Then, Herring Bradley bought 1,533 shares, generating $17,601 in total proceeds.
Before that, Campobasso Matthew bought 1,081 shares. Enfusion Inc shares valued at $12,411 were divested by the Officer at a price of $11.48 per share.
A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in late February from “a Neutral” to “a Sell”. JP Morgan also remained covering ENFN and has decreased its forecast on January 30, 2024 with a “an Underweight” recommendation from previously “Neutral” rating. UBS started covering the stock on November 07, 2023. It rated ENFN as “a Neutral”.
Price Performance Review of ENFN
On Tuesday, Enfusion Inc [NYSE:ENFN] saw its stock jump 0.26% to $11.40. Over the last five days, the stock has gained 0.09%. Enfusion Inc shares have risen nearly 10.68% since the year began. Nevertheless, the stocks have risen 31.49% over the past one year. While a 52-week high of $11.80 was reached on 02/20/25, a 52-week low of $7.83 was recorded on 01/02/25. SMA at 50 days reached $10.92, while 200 days put it at $9.49.
Levels Of Support And Resistance For ENFN Stock
The 24-hour chart illustrates a support level at 11.27, which if violated will result in even more drops to 11.15. On the upside, there is a resistance level at 11.49. A further resistance level may holdings at 11.59. The Relative Strength Index (RSI) on the 14-day chart is 59.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.45%. Stochastics %K at 56.44% indicates the stock is a holding.
The most recent change occurred on April 03, 2023 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $11 price target.
